Common Contracts
5 similar Research and License Agreement contracts by Revium Rx., Scopus BioPharma Inc., Therapix Biosciences Ltd.
RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • February 14th, 2025 • Revium Rx.
This Research and License Agreement (“Agreement”) is made in Jerusalem 24th day of November 2022 (the “Effective Date”), by and between YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”) of the first part, and LIPOVAC LTD., Company No. 516352408, of 10 Dover Shalom, Beit Shemesh, Israel (the “Company”), of the second part (each of Yissum and the Company, a “Party”, and collectively the “Parties”).
RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • February 14th, 2025 • Revium Rx.
This Research and License Agreement (“Agreement”) is made in Jerusalem 24th day of November 2022 (the “Effective Date”), by and between YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”) of the first part, and LIPOVAC LTD., Company No. 516352408, of 10 Dover Shalom, Beit Shemesh, Israel (the “Company”), of the second part (each of Yissum and the Company, a “Party”, and collectively the “Parties”)
RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • August 15th, 2019 • Scopus BioPharma Inc. • Pharmaceutical preparations
This Research and License Agreement (“Agreement”) is made in Jerusalem this 8 day of August 2019 (the “Effective Date”), by and between:
REDACTEDResearch and License Agreement • June 19th, 2019 • Scopus BioPharma Inc. • Pharmaceutical preparations
*Certain identified information has been excluded from the exhibit because it is both: (i) not material and (ii) would be competitively harmful if publicly disclosed.*
ContractResearch and License Agreement • May 15th, 2019 • Therapix Biosciences Ltd. • Pharmaceutical preparations
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THERAPIX BIOSCIENCES LTD. IF PUBLICLY DISCLOSED. OMISSIONS ARE DENOTED IN BRACKETS THROUGHOUT THIS EXHIBIT.